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Background
Quality of Life (QOL) assessment is important in onco-
logy studies. Effect of therapy on QOL is important in
HIV-KS, as decreasing morbidity is a goal of therapy.
This is the first prospective study to evaluate the effect of
HAART, +/- chemotherapy, on QOL in African patients
with HIV-KS. Within the KAART study, we assessed the
impact of HAART over 12 months in all patients, differ-
ences in QOL between arms, as well as associations
between QOL and several clinical parameters.
Methods
KAART is a randomized, controlled, open label trial of
HAART vs. HAART plus chemotherapy (CXT) in treat-
ment-naive South African patients with HIV-KS. QOL
outcomes were assessed prospectively in English or isiZulu
using EORTC-QOL30. We evaluated intra-group changes
between baseline and month 12 QOL scores (Wilcoxon
rank sign test), changes between baseline and month 12
QOL scores between the two groups (Mann-Whitney
test), and the relationship between clinical responses and
global QOL (Kruskal-Wallis test). Given multiple compari-
sons, p-values <0.01 are considered statistically significant;
0.01< p <0.05 represent important trends.
Results
111 participants had QOL information. Median global
health score (perfect score = 100) was 50 at baseline,
improving to 67 at month 12 (p<0.001). Significant
improvements in median scores from baseline to month
12 were seen in emotional, cognitive, and social scales,
but not physical function and role function. Most symp-
tom scales (fatigue, pain, dyspnea, insomnia, appetite,
diarrhea, and constipation) showed significant improve-
ment over time. Improvement in nausea was borderline
(p=0.03). There were no statistically significant changes
over time between arms; however role function
(p=0.011) trended toward greater improvement in the
CXT arm. Complete or partial response was associated
with increased global health scores (p<0.001), while
number or severity of adverse events, adherence, HIV
viral load, or CD4 count were not.
Conclusion
African HIV-KS patients benefit significantly in their
overall global health status, functioning and symptoms
from HAART. Partial and complete responses to therapy
are significant predictors of global health, and the role of
early chemotherapy in advanced HIV-KS merits further
investigation. Improving QOL is an important goal in the
treatment of advanced KS in resource-limited settings.
QOL results from this study inform treatment paradigms
for management of African patients with HIV-KS.
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